Global Migraine Drugs Market 2015-2019
出 版 商：Infiniti Research
出版日期：2015/02/04
頁 數：110頁
文件格式：PDF
價 格：
USD 3,000 (Single-User License)
USD 3,500 (Multi-User License)
USD 4,500 (Global-User License)
USD 3,500 (Multi-User License)
USD 4,500 (Global-User License)
About Migraine
Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines.
TechNavio's analysts forecast the Global Migraine Drugs market to grow at a CAGR of 3.54 percent over the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the Global Migraine Drugs market for the period 2015–2019. The Global Migraine Drugs market can be divided into two segments: Selective Serotonin Receptor (5- HTI) Agonists/ Triptans and Ergot Alkaloids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment and prevention of migraine that are available in the market.
TechNavio's report, the Global Migraine Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region, and the EMEA region; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ Abbott
‧ Allergan
‧ Eisai
‧ Endo
‧ GlaxoSmithKline
‧ Impax Laboratories
‧ Pfizer
Other Prominent Vendors
‧ Almirall
‧ Amgen
‧ AstraZeneca
‧ Boehringer Ingelheim
‧ Eli Lilly
‧ IntelGenx Technologies
‧ Johnson & Johnson
‧ Nautilus
‧ OptiNose
‧ RedHill Biopharma
‧ Zogenix
Market Driver
‧ Increase in Prevalence of Migraine
‧ For a full, detailed list, view our report
Market Challenge
‧ High Cost of Drugs
‧ For a full, detailed list, view our report
Market Trend
‧ Increase in Strategic Collaborations
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2019 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines.
TechNavio's analysts forecast the Global Migraine Drugs market to grow at a CAGR of 3.54 percent over the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the Global Migraine Drugs market for the period 2015–2019. The Global Migraine Drugs market can be divided into two segments: Selective Serotonin Receptor (5- HTI) Agonists/ Triptans and Ergot Alkaloids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment and prevention of migraine that are available in the market.
TechNavio's report, the Global Migraine Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region, and the EMEA region; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ Abbott
‧ Allergan
‧ Eisai
‧ Endo
‧ GlaxoSmithKline
‧ Impax Laboratories
‧ Pfizer
Other Prominent Vendors
‧ Almirall
‧ Amgen
‧ AstraZeneca
‧ Boehringer Ingelheim
‧ Eli Lilly
‧ IntelGenx Technologies
‧ Johnson & Johnson
‧ Nautilus
‧ OptiNose
‧ RedHill Biopharma
‧ Zogenix
Market Driver
‧ Increase in Prevalence of Migraine
‧ For a full, detailed list, view our report
Market Challenge
‧ High Cost of Drugs
‧ For a full, detailed list, view our report
Market Trend
‧ Increase in Strategic Collaborations
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2019 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Migraine Pipeline Snapshot
08. Migraine Pipeline Assessment
09. Market Segmentation by Therapeutic Class
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Abbott Laboratories
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011 and 2012
19.1.7 Revenue by Geographical Segmentation
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Allergan
19.2.1 Key Facts
19.2.2 Business Description
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue
19.2.5 Business Segmentation by Revenue 2011-2013
19.2.6 Geographical Segmentation by Revenue
19.2.7 Business Strategy
19.2.8 Key Developments
19.2.9 SWOT Analysis
19.3 Eisai
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Comparison between Revenue, Operating Income, and Net Income
19.3.4 Sales by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 Endo International
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Geographical Segmentation by Revenue 2013
19.4.6 Business Strategy
19.4.7 Recent Developments
19.4.8 SWOT Analysis
19.5 GlaxoSmithKline
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Sales by Geography
19.5.6 Pipeline Products
19.5.7 Business Strategy
19.5.8 Key Information
19.5.9 SWOT Analysis
19.6 Impax Laboratories
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation by Revenue 2013
19.6.4 Business Segmentation by Revenue 2012 and 2013
19.6.5 Geographical Segmentation
19.6.6 Business Strategy
19.6.7 Recent Developments
19.6.8 SWOT Analysis
19.7 Pfizer
19.7.1 Key Facts
19.7.2 Business Overview
19.7.3 Business Segmentation by Revenue 2013
19.7.4 Business Segmentation by Revenue 2012 and 2013
19.7.5 Geographical Segmentation by Revenue
19.7.6 Business Strategy
19.7.7 Key Developments
19.7.8 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Migraine Drugs Market 2014-2019 (US$ billion)
Exhibit 3: Migraine: Clinical Developmental Pipeline
Exhibit 4: Migraine Clinical Trials by Status
Exhibit 5: Migraine Clinical Trials by Phase
Exhibit 6: Global Migraine Drugs Market Segmentation by Therapeutic Class
Exhibit 7: Global Migraine Drugs Market Segmentation by Therapeutic Class 2014
Exhibit 8: Global Migraine Drugs Market by Geographical Segmentation 2014
Exhibit 9: Age and Gender Specific Prevalence of Migraine
Exhibit 10: Abbott Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 11: Abbott Product Portfolio 2013
Exhibit 12: Allergan Worldwide Sales 2013
Exhibit 13: Allergan Botox/Neuromodulator Sales 2013 (US$ million)
Exhibit 14: Eisai Year on Year Sales Comparison 2010-2012 (US$ billion)
Exhibit 15: Eisai Net Sales by Reporting Segment 2014
Exhibit 16: Endo International Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 17: GlaxoSmithKline Treximet Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 18: GlaxoSmithKline Treximet Year on Year Sales Comparison 2010-2012 (US$ million)
Exhibit 19: GlaxoSmithKline Imigran/Imitrex Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 20: Imapx Laboratories Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 21: Impax Laboratories Generic Products Percentage Share 2013
Exhibit 22: Pfizer Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 23: Pfizer Relpax Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 24: Abbott Laboratories Inc.: Business Segmentation
Exhibit 25: Abbott Laboratories Inc.: Revenue by Business Segmentation 2012
Exhibit 26: Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)
Exhibit 27: Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012
Exhibit 28: Allergan: Business Segmentation
Exhibit 29: Allergan: Business Segmentation by Revenue 2013
Exhibit 30: Allergan: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 31: Allergan: Geographical Segmentation by Revenue 2013
Exhibit 32: Eisai Co. Ltd.: Comparison between Revenue, Operating Income, and Net Income 2011-2013 (US$ billion)
Exhibit 33: Eisai Co. Ltd.: Sales by Geography 2013 (US$ billion)
Exhibit 34: Endo International: Business Segmentation by Revenue 2013
Exhibit 35: Endo International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 36: Endo International: Geographical Segmentation by Revenue 2013
Exhibit 37: GlaxoSmithKline: Business Segmentation 2013
Exhibit 38: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 39: GlaxoSmithKline: Sales by Geography 2013
Exhibit 40: GlaxoSmithKline: Pipeline Products 2013
Exhibit 41: Impax Laboratories: Business Segmentation by Revenue 2013
Exhibit 42: Impax Laboratories: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 43: Impax Laboratories: Geographical Segmentation
Exhibit 44: Pfizer: Business Segmentation by Revenue 2013
Exhibit 45: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 46: Pfizer: Geographical Segmentation by Revenue 2013
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Migraine Pipeline Snapshot
08. Migraine Pipeline Assessment
09. Market Segmentation by Therapeutic Class
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Abbott Laboratories
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011 and 2012
19.1.7 Revenue by Geographical Segmentation
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Allergan
19.2.1 Key Facts
19.2.2 Business Description
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue
19.2.5 Business Segmentation by Revenue 2011-2013
19.2.6 Geographical Segmentation by Revenue
19.2.7 Business Strategy
19.2.8 Key Developments
19.2.9 SWOT Analysis
19.3 Eisai
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Comparison between Revenue, Operating Income, and Net Income
19.3.4 Sales by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 Endo International
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Geographical Segmentation by Revenue 2013
19.4.6 Business Strategy
19.4.7 Recent Developments
19.4.8 SWOT Analysis
19.5 GlaxoSmithKline
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Sales by Geography
19.5.6 Pipeline Products
19.5.7 Business Strategy
19.5.8 Key Information
19.5.9 SWOT Analysis
19.6 Impax Laboratories
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation by Revenue 2013
19.6.4 Business Segmentation by Revenue 2012 and 2013
19.6.5 Geographical Segmentation
19.6.6 Business Strategy
19.6.7 Recent Developments
19.6.8 SWOT Analysis
19.7 Pfizer
19.7.1 Key Facts
19.7.2 Business Overview
19.7.3 Business Segmentation by Revenue 2013
19.7.4 Business Segmentation by Revenue 2012 and 2013
19.7.5 Geographical Segmentation by Revenue
19.7.6 Business Strategy
19.7.7 Key Developments
19.7.8 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Migraine Drugs Market 2014-2019 (US$ billion)
Exhibit 3: Migraine: Clinical Developmental Pipeline
Exhibit 4: Migraine Clinical Trials by Status
Exhibit 5: Migraine Clinical Trials by Phase
Exhibit 6: Global Migraine Drugs Market Segmentation by Therapeutic Class
Exhibit 7: Global Migraine Drugs Market Segmentation by Therapeutic Class 2014
Exhibit 8: Global Migraine Drugs Market by Geographical Segmentation 2014
Exhibit 9: Age and Gender Specific Prevalence of Migraine
Exhibit 10: Abbott Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 11: Abbott Product Portfolio 2013
Exhibit 12: Allergan Worldwide Sales 2013
Exhibit 13: Allergan Botox/Neuromodulator Sales 2013 (US$ million)
Exhibit 14: Eisai Year on Year Sales Comparison 2010-2012 (US$ billion)
Exhibit 15: Eisai Net Sales by Reporting Segment 2014
Exhibit 16: Endo International Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 17: GlaxoSmithKline Treximet Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 18: GlaxoSmithKline Treximet Year on Year Sales Comparison 2010-2012 (US$ million)
Exhibit 19: GlaxoSmithKline Imigran/Imitrex Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 20: Imapx Laboratories Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 21: Impax Laboratories Generic Products Percentage Share 2013
Exhibit 22: Pfizer Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 23: Pfizer Relpax Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 24: Abbott Laboratories Inc.: Business Segmentation
Exhibit 25: Abbott Laboratories Inc.: Revenue by Business Segmentation 2012
Exhibit 26: Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)
Exhibit 27: Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012
Exhibit 28: Allergan: Business Segmentation
Exhibit 29: Allergan: Business Segmentation by Revenue 2013
Exhibit 30: Allergan: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 31: Allergan: Geographical Segmentation by Revenue 2013
Exhibit 32: Eisai Co. Ltd.: Comparison between Revenue, Operating Income, and Net Income 2011-2013 (US$ billion)
Exhibit 33: Eisai Co. Ltd.: Sales by Geography 2013 (US$ billion)
Exhibit 34: Endo International: Business Segmentation by Revenue 2013
Exhibit 35: Endo International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 36: Endo International: Geographical Segmentation by Revenue 2013
Exhibit 37: GlaxoSmithKline: Business Segmentation 2013
Exhibit 38: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 39: GlaxoSmithKline: Sales by Geography 2013
Exhibit 40: GlaxoSmithKline: Pipeline Products 2013
Exhibit 41: Impax Laboratories: Business Segmentation by Revenue 2013
Exhibit 42: Impax Laboratories: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 43: Impax Laboratories: Geographical Segmentation
Exhibit 44: Pfizer: Business Segmentation by Revenue 2013
Exhibit 45: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 46: Pfizer: Geographical Segmentation by Revenue 2013
